541 related articles for article (PubMed ID: 19038212)
1. Linking Abeta and tau in late-onset Alzheimer's disease: a dual pathway hypothesis.
Small SA; Duff K
Neuron; 2008 Nov; 60(4):534-42. PubMed ID: 19038212
[TBL] [Abstract][Full Text] [Related]
2. A Theoretical Analysis of the Synergy of Amyloid and Tau in Alzheimer's Disease.
Han P; Shi J
J Alzheimers Dis; 2016 Apr; 52(4):1461-70. PubMed ID: 27104897
[TBL] [Abstract][Full Text] [Related]
3. Abeta, tau and ApoE4 in Alzheimer's disease: the axonal connection.
Adalbert R; Gilley J; Coleman MP
Trends Mol Med; 2007 Apr; 13(4):135-42. PubMed ID: 17344096
[TBL] [Abstract][Full Text] [Related]
4. Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease.
Vemuri P; Wiste HJ; Weigand SD; Knopman DS; Shaw LM; Trojanowski JQ; Aisen PS; Weiner M; Petersen RC; Jack CR;
Ann Neurol; 2010 Mar; 67(3):308-16. PubMed ID: 20373342
[TBL] [Abstract][Full Text] [Related]
5. APOE Antibody Inhibits Aβ-Associated Tau Seeding and Spreading in a Mouse Model.
Gratuze M; Jiang H; Wang C; Xiong M; Bao X; Holtzman DM
Ann Neurol; 2022 Jun; 91(6):847-852. PubMed ID: 35285073
[TBL] [Abstract][Full Text] [Related]
6. Genetically augmenting tau levels does not modulate the onset or progression of Abeta pathology in transgenic mice.
Oddo S; Caccamo A; Cheng D; Jouleh B; Torp R; LaFerla FM
J Neurochem; 2007 Aug; 102(4):1053-63. PubMed ID: 17472708
[TBL] [Abstract][Full Text] [Related]
7. [Transmission of pathogenic protein aggregates in Alzheimer's disease].
Schwarzman AL; Sarantseva SV
Mol Biol (Mosk); 2017; 51(3):418-422. PubMed ID: 28707657
[TBL] [Abstract][Full Text] [Related]
8. Endogenous Apolipoprotein E (ApoE) Fragmentation Is Linked to Amyloid Pathology in Transgenic Mouse Models of Alzheimer's Disease.
Saul A; Wirths O
Mol Neurobiol; 2017 Jan; 54(1):319-327. PubMed ID: 26742512
[TBL] [Abstract][Full Text] [Related]
9. Human apolipoprotein E redistributes fibrillar amyloid deposition in Tg-SwDI mice.
Xu F; Vitek MP; Colton CA; Previti ML; Gharkholonarehe N; Davis J; Van Nostrand WE
J Neurosci; 2008 May; 28(20):5312-20. PubMed ID: 18480287
[TBL] [Abstract][Full Text] [Related]
10. APOE effects on regional tau in preclinical Alzheimer's disease.
Young CB; Johns E; Kennedy G; Belloy ME; Insel PS; Greicius MD; Sperling RA; Johnson KA; Poston KL; Mormino EC; ;
Mol Neurodegener; 2023 Jan; 18(1):1. PubMed ID: 36597122
[TBL] [Abstract][Full Text] [Related]
11. Protein aggregation in Alzheimer's disease: Aβ and τ and their potential roles in the pathogenesis of AD.
Thal DR; Fändrich M
Acta Neuropathol; 2015 Feb; 129(2):163-5. PubMed ID: 25600324
[No Abstract] [Full Text] [Related]
12. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade.
Jack CR; Knopman DS; Jagust WJ; Shaw LM; Aisen PS; Weiner MW; Petersen RC; Trojanowski JQ
Lancet Neurol; 2010 Jan; 9(1):119-28. PubMed ID: 20083042
[TBL] [Abstract][Full Text] [Related]
13. Cellular cholesterol homeostasis and Alzheimer's disease.
Chang TY; Yamauchi Y; Hasan MT; Chang C
J Lipid Res; 2017 Dec; 58(12):2239-2254. PubMed ID: 28298292
[TBL] [Abstract][Full Text] [Related]
14. New Insights into the Spontaneous Human Alzheimer's Disease-Like Model Octodon degus: Unraveling Amyloid-β Peptide Aggregation and Age-Related Amyloid Pathology.
Cisternas P; Zolezzi JM; Lindsay C; Rivera DS; Martinez A; Bozinovic F; Inestrosa NC
J Alzheimers Dis; 2018; 66(3):1145-1163. PubMed ID: 30412496
[TBL] [Abstract][Full Text] [Related]
15. Aβ and tau prion-like activities decline with longevity in the Alzheimer's disease human brain.
Aoyagi A; Condello C; Stöhr J; Yue W; Rivera BM; Lee JC; Woerman AL; Halliday G; van Duinen S; Ingelsson M; Lannfelt L; Graff C; Bird TD; Keene CD; Seeley WW; DeGrado WF; Prusiner SB
Sci Transl Med; 2019 May; 11(490):. PubMed ID: 31043574
[TBL] [Abstract][Full Text] [Related]
16. Exploring the Role of Aggregated Proteomes in the Pathogenesis of Alzheimer's Disease.
Narayanan SE; Sekhar N; Rajamma RG; Marathakam A; Al Mamun A; Uddin MS; Mathew B
Curr Protein Pept Sci; 2020; 21(12):1164-1173. PubMed ID: 32957903
[TBL] [Abstract][Full Text] [Related]
17. APP/PS1 mice overexpressing SREBP-2 exhibit combined Aβ accumulation and tau pathology underlying Alzheimer's disease.
Barbero-Camps E; Fernández A; Martínez L; Fernández-Checa JC; Colell A
Hum Mol Genet; 2013 Sep; 22(17):3460-76. PubMed ID: 23648430
[TBL] [Abstract][Full Text] [Related]
18. Synergy between amyloid-β and tau in Alzheimer's disease.
Busche MA; Hyman BT
Nat Neurosci; 2020 Oct; 23(10):1183-1193. PubMed ID: 32778792
[TBL] [Abstract][Full Text] [Related]
19. What's next for Alzheimer treatment?: while Aβ isn't out of the picture yet, several other therapeutic routes are being explored.
Schwartz A
Ann Neurol; 2013 Apr; 73(4):A7-9. PubMed ID: 24643982
[No Abstract] [Full Text] [Related]
20. Molecular Insight into the Therapeutic Promise of Flavonoids against Alzheimer's Disease.
Uddin MS; Kabir MT; Niaz K; Jeandet P; Clément C; Mathew B; Rauf A; Rengasamy KRR; Sobarzo-Sánchez E; Ashraf GM; Aleya L
Molecules; 2020 Mar; 25(6):. PubMed ID: 32168835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
